Buchumschlag

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia

A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years mainten...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lengfelder, Eva (VerfasserIn) , Reichert, A. (VerfasserIn) , Haferlach, Claudia (VerfasserIn) , Haase, D. (VerfasserIn) , Haferlach, T. (VerfasserIn) , Löffler, H. (VerfasserIn) , Staib, P. (VerfasserIn) , Heyll, A. (VerfasserIn) , Seifarth, Wolfgang (VerfasserIn) , Saußele, Susanne (VerfasserIn) , Fonatsch, C. (VerfasserIn) , Gassmann, Winfried (VerfasserIn) , Ludwig, Wolf-Dieter (VerfasserIn) , Hochhaus, Andreas (VerfasserIn) , Beelen, D. (VerfasserIn) , Aul, C. (VerfasserIn) , Sauerland, M.-C. (VerfasserIn) , Heinecke, A. (VerfasserIn) , Hehlmann, Rüdiger (VerfasserIn) , Wörmann, B. (VerfasserIn) , Hiddemann, W. (VerfasserIn) , Büchner, T. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 04 August 2000
In: Leukemia
Year: 2000, Jahrgang: 14, Heft: 8, Pages: 1362-1370
ISSN:1476-5551
DOI:10.1038/sj.leu.2401843
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2401843
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2401843
Volltext
Verfasserangaben:E. Lengfelder, A. Reichert, C. Schoch, D. Haase, T. Haferlach, H. Löffler, P. Staib, A. Heyll, W. Seifarth, S. Saussele, C. Fonatsch, W. Gassmann, W.-D. Ludwig, A. Hochhaus, D. Beelen, C. Aul, M.-C. Sauerland, A. Heinecke, R. Hehlmann, B. Wörmann, W. Hiddemann, T. Büchner
Beschreibung
Zusammenfassung:A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years maintenance therapy. Fifty-one patients, diagnosed and monitored from December 1994 to June 1999, were evaluated. The median age was 43 (16-60) years. The morphologic diagnosis was M3 in 40 (78%) and M3v in 11 (22%) patients. In 15 (30%) patients the initial white blood cell counts were ⩾5 × 109/l. The cytogenetic or molecular proof of the translocation t(15;17) was a mandatory prerequisite for eligibility. The diagnosis was confirmed by karyotyping in 46 and by RT-PCR of the PML/RARα transcript in 45 cases. The rate of complete hematological remission was 92% and the early death rate 8%. Monitoring of minimal residual disease by RT-PCR of PML/RARα (sensitivity 10−4) showed negativity in 29 of 32 (91%) evaluable cases after induction, in 23 of 25 (92%) after consolidation, and in 27 of 30 (90%) during maintenance, after a median time of 2, 4 and of 18 months after diagnosis, respectively. After a median follow-up of 27 months, the estimated actuarial 2 years overall and event-free survival were both 88% (79, 97), and the 2 years relapse-free survival 96% (90, 100). The high antileukemic efficacy of this treatment strategy is demonstrated by a rapid and extensive reduction of the malignant clone and by a low relapse rate. The results suggest that the intensity of the induction chemotherapy combined with ATRA is one of the factors which may have a critical influence on the outcome of APL. A randomized trial should assess the value of an induction therapy including ATRA and high-dose ara-C in comparison to standard-dose ara-C.
Beschreibung:Gesehen am 13.04.2022
Beschreibung:Online Resource
ISSN:1476-5551
DOI:10.1038/sj.leu.2401843

Ähnliche Einträge